irofulven has been researched along with Neuroectodermal Tumors, Primitive in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Billups, C; Cheshire, PJ; Fouladi, M; Friedman, HS; Houghton, PJ; Leggas, M; Peterson, JK; Stewart, CF; Woo, MH | 1 |
1 other study(ies) available for irofulven and Neuroectodermal Tumors, Primitive
| Article | Year |
|---|---|
Relation between Irofulven (MGI-114) systemic exposure and tumor response in human solid tumor xenografts.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Child; Chromatography, High Pressure Liquid; Cyclophosphamide; Dacarbazine; Dactinomycin; Disease-Free Survival; Doxorubicin; Female; Glioblastoma; Glioma; Humans; Medulloblastoma; Mice; Mice, Inbred CBA; Mice, Inbred ICR; Mice, SCID; Neoplasms; Neuroblastoma; Neuroectodermal Tumors, Primitive; Radiation Chimera; Random Allocation; Rhabdoid Tumor; Rhabdomyosarcoma, Embryonal; Sesquiterpenes; Tumor Cells, Cultured; Vincristine; Xenograft Model Antitumor Assays | 2002 |